Uncommon_Mutations_Database Uncommon_Mutations_Database New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
SPEVIGO approved expanded indications China US SPEVIGO approved expanded indications China US SPEVIGO® approved for expanded indications in China and the US
2021 PRRS Research Award winners announced 2021 PRRS Research Award winners announced The 2021 European PRRS Research Award winners announced
First Translational Medicine Award awarded First Translational Medicine Award awarded The Award recognizes the research that has the highest translational potential
Protein Degraders in Cancer Protein Degraders in Cancer Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Blue internal teat sealant now in dairy mastitis portfolio Blue internal teat sealant now in dairy mastitis portfolio Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors
FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Largest European development center for biotechnology Largest European development center for biotechnology Boehringer Ingelheim inaugurates largest European development center for biotechnology
ATM-Ranking-2021 ATM-Ranking-2021 Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
bix_facilitates_global_partnerships bix_facilitates_global_partnerships BI X focuses on partnerships to speed up the development of digital healthcare solutions
PREVEXXION® RN: Marek’s disease vaccine available in EU UK PREVEXXION® RN: Marek’s disease vaccine available in EU UK Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
digital_leader_award_2020 digital_leader_award_2020 Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
Do you take periodontal disease in dogs seriously? We do! Do you take periodontal disease in dogs seriously? We do! Periodontal Disease? Brushing teeth is vital to prevent doggy breath, but not enough to ensure animal health and well-being
Boehringer Ingelheim advances SIRP immune-oncology program Boehringer Ingelheim advances SIRP immune-oncology program Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Monoclonal antibodies Boehringer Ingelheim and Invetx Monoclonal antibodies Boehringer Ingelheim and Invetx Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Chronic kidney disease in cats Chronic kidney disease in cats Detect and manage chronic kidney disease and high blood pressure in cats
Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
FreVAX smartphone application piglet vaccination FreVAX smartphone application piglet vaccination New FreVAX™ smartphone application brings piglet vaccination to another level
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Phase II clinical trial weight loss results Phase II clinical trial weight loss results Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
European_Commission_approves_nintedanibSSc-ILD European_Commission_approves_nintedanibSSc-ILD Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Aservo EquiHaler wins Pharmapack Award 2021 Aservo EquiHaler wins Pharmapack Award 2021 Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
Research ruminant animal health well-being Research ruminant animal health well-being Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research